| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF02788419 |
| P698 | PubMed publication ID | 9873951 |
| P2093 | author name string | W E Fisher | |
| W J Schirmer | |||
| P Muscarella | |||
| L G Boros | |||
| P2860 | cites work | Epidermal growth factor-like transforming growth factor. II. Interaction with epidermal growth factor receptors in human placenta membranes and A431 cells | Q28586916 |
| Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects | Q33506131 | ||
| Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase | Q33844684 | ||
| Pancreastatin and islet hormone release | Q34354879 | ||
| Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle | Q34359163 | ||
| Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone | Q34598135 | ||
| Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides | Q34713867 | ||
| Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer | Q35616781 | ||
| Hormonal control of pancreatic growth | Q35899707 | ||
| Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. | Q36245969 | ||
| Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations | Q40118368 | ||
| Hormone receptors. An update and application. | Q40197948 | ||
| Molecular mechanisms of antiproliferative effect of somatostatin: involvement of a tyrosine phosphatase | Q41081364 | ||
| Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotide | Q41181809 | ||
| Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors | Q41195938 | ||
| Cholecystokinin receptors and PANC-1 human pancreatic cancer cells | Q41544608 | ||
| Binding of epidermal growth factor in rat pancreatic acini | Q41555819 | ||
| Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. | Q41586378 | ||
| Human pancreatic cancer cell lines do not express receptors for somatostatin | Q41606257 | ||
| Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice | Q41635101 | ||
| Growth inhibition of human pancreatic cancer cells by cholecystokinin receptor antagonist in tissue culture and in nude mice | Q41641498 | ||
| CCK stimulates growth of six human pancreatic cancer cell lines in serum-free medium | Q41694806 | ||
| Effects of insulin and somatostatin on the growth and the colony formation of two human pancreatic cancer cell lines | Q41707613 | ||
| Effects of a high-fat diet and L364,718 on growth of human pancreas cancer | Q41731843 | ||
| Insulin-like growth factor I and transforming growth factor alpha as autocrine growth factors in human pancreatic cancer cell growth | Q41753654 | ||
| Pancreatic cancer in the Syrian hamster induced by N-nitrosobis(2-oxopropyl)-amine: cocarcinogenic effect of epidermal growth factor. | Q41861412 | ||
| Role of cholecystokinin in dietary fat-promoted azaserine-induced pancreatic carcinogenesis in rats | Q42371569 | ||
| Therapeutic effect of the gastrin receptor antagonist, CR2093 on gastrointestinal tumour cell growth | Q42371954 | ||
| Pancreatic carcinogenesis-enhancement by cholecystokinin in the hamster-nitrosamine model | Q42374570 | ||
| Inhibitory effect of pancreastatin on pancreatic exocrine secretion in the conscious rat. | Q42490468 | ||
| Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters | Q43616260 | ||
| Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion | Q43681165 | ||
| Neuropeptide Y and peptide YY stimulate the growth of exocrine pancreatic carcinoma cells | Q43893745 | ||
| Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules | Q44049682 | ||
| Influence of cholecystokinin antagonist on the effects of cholecystokinin and bombesin on azaserine-induced lesions in rat pancreas | Q44117057 | ||
| Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study | Q44163343 | ||
| Pancreatic carcinogenesis: effect of secretin in the hamster- nitrosamine model | Q44364140 | ||
| VIP regulation of a human pancreatic cancer cell line: Capan-1. | Q44412231 | ||
| Effects of cholecystokinin and bombesin on development of azaserine-induced pancreatic tumours in rats: modulation by the cholecystokinin receptor antagonist lorglumide | Q45254181 | ||
| Y2 receptors decrease human pancreatic cancer growth and intracellular cyclic adenosine monophosphate levels | Q46112020 | ||
| Effect of CCK receptor antagonist on growth of pancreatic adenocarcinoma | Q46507630 | ||
| Effects of sandostatin and castration on pancreatic carcinogenesis in rats and hamsters | Q46540777 | ||
| Evaluation of receptors for somatostatin in various tumors using different analogs | Q49091725 | ||
| Human pancreatic cancer growth is inhibited by peptide YY and BIM-43004-1. | Q50760925 | ||
| Effects of pancreastatin (24-49) on growth of normal pancreas and pancreatic cancer. | Q51609438 | ||
| Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995. | Q52828506 | ||
| A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer | Q53027312 | ||
| Overexpression of cholecystokinin receptors in azaserine-induced neoplasms of the rat pancreas | Q53489462 | ||
| Effects of bombesin on the development of N-nitrosobis(2-oxopropyl)amine-induced pancreatic lesions in hamsters. | Q53497377 | ||
| Effect of secretin on pancreatic carcinogenesis in the hamster model. | Q53514510 | ||
| Study into the role of cholecystokinin in bombesin-stimulated pancreatic growth in rats and hamsters. | Q53516701 | ||
| Effect of cholecystokinin on pancreatic carcinogenesis in the hamster model. | Q53523032 | ||
| Studies of the effect of cerulein administration on experimental pancreatic carcinogenesis. | Q53555239 | ||
| Cholecystokinin inhibits pancreatic and hepatic carcinogenesis. | Q53562019 | ||
| Presence of VIP receptors in a human pancreatic adenocarcinoma cell line. Modulation of the cAMP response during cell proliferation | Q67283522 | ||
| Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). The French Associations for Surgical Research | Q67522479 | ||
| Gastrin-releasing peptide: in vivo and in vitro growth effects on an acinar pancreatic carcinoma | Q67852017 | ||
| Vasoactive intestinal peptide inhibits the growth of hamster pancreatic cancer but not human pancreatic cancer in vivo | Q67940551 | ||
| Cholecystokinin inhibits DNA alkylation induced by N-nitrosobis (2-oxopropyl)amine (BOP) in hamster pancreas | Q68141109 | ||
| Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters | Q68321464 | ||
| Specific binding of cholecystokinin, estradiol and somatostatin to human pancreatic cancer xenografts | Q68325510 | ||
| Effect of somatostatin and tamoxifen on the growth of human pancreatic cancers in nude mice | Q68452168 | ||
| Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990 | Q68581002 | ||
| Candidate hormones of the gut. I. Introduction | Q68788143 | ||
| Response to exogenous cholecystokinin of six human gastrointestinal cancers xenografted in nude mice | Q69059131 | ||
| Membrane receptors for peptides in experimental and human pancreatic cancers | Q69375881 | ||
| Bombesin inhibits growth of human pancreatic adenocarcinoma in nude mice | Q69831032 | ||
| Hormonal control of pancreatic cancer growth | Q69898848 | ||
| Inhibition of growth of a transplanted rat pancreatic acinar carcinoma with CCK-8 | Q70628201 | ||
| Treatment with Secretin and a Cholecystokinin-Like Peptide in Patients with Pancreatic Cancer | Q72382853 | ||
| Trophic action of epidermal growth factor on the pancreas and gastroduodenal mucosa in rats | Q72674216 | ||
| Effects of chronic administration of somatostatin on rat exocrine pancreas | Q72677409 | ||
| Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors | Q72741141 | ||
| Adenocarcinoma of the human exocrine pancreas : Presence of secretin and caerulein receptors | Q72916942 | ||
| Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters | Q72969104 | ||
| P433 | issue | 3 | |
| P921 | main subject | pancreatic adenocarcinoma | Q18556189 |
| P304 | page(s) | 169-180 | |
| P577 | publication date | 1998-12-01 | |
| P1433 | published in | International Journal of Pancreatology | Q27711541 |
| P1476 | title | Gastrointestinal hormones as potential adjuvant treatment of exocrine pancreatic adenocarcinoma | |
| P478 | volume | 24 |
Search more.